There is evidence to suggest that tirzepatide may increase the risk of bone fractures, particularly in which glp-1 is fda approved for weight loss older adults or those with existing risk factors for osteoporosis. Bone fractures can have serious consequences.
There is evidence to suggest that tirzepatide may increase the risk of bone fractures, particularly in which glp-1 is fda approved for weight loss older adults or those with existing risk factors for osteoporosis. Bone fractures can have serious consequences.